Clinical trial
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin…
NCT00060944 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00060944 |
|---|---|
| Title | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer |
| Official title | A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | PharmaMar Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liposarcoma, Leiomyosarcoma |
| Intervention type | Drug |
| Interventions | Yondelis, Dexamethasone |
| Enrollment | 271 |
| Start date | May 1, 2003 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 19, 2003 |
| Last update posted | Sep 8, 2014 |
| Countries | Australia, Belgium, Canada, France, Germany, Russia, Spain, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: